Corcept Therapeutics shareholders approve 2024 Incentive Award Plan adding 8M new shares

CORCEPT THERAPEUTICS INC

2024 Plan replaces 2012 plan; total shares authorized = 8M new + 4,073,955 carryover + lapsed awards.
All 9 director nominees elected; vote range 56.9M to 65.6M for (excluding broker non-votes).
Ernst & Young ratified as auditor for FY2024: 86.6M for, 1.7M against.
Advisory say-on-pay approved: 64.5M for, 1.0M against; 22.5M broker non-votes.
2024 Plan passed with 47.0M for, 18.7M against; 22.5M broker non-votes.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.